PUBLICATIONS
| A/A | Title | Authors | Journal |
| 1 | Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. | Souglakos J, Kotsakis A, Kouroussis C, Kakolyris S, Mavroudis D, Kalbakis K, Agelaki S, Vlachonikolis J, Georgoulias V, Samonis G. | Cancer. 2002 Sep 15.95(6):1326-33. doi:10.1002/cncr.10802.
PMID: 12216102 |
| 2 | Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. | Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V. | Oncology. 2002.
PMID: 12065868 Clinical Trial. |
| 3 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. | Koukourakis MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, Retalis G, Georgoulias V; Tumor and Angiogenesis Research Group. | Int J Radiat Oncol Biol Phys. 2002 Jan 1.52(1):144-55.
doi: 10.1016/s0360-3016(01)01759-x. PMID: 11777632 |
| 4 | Incidence of breast cancer on Crete, 1994-1995. | Vlachonikolis IG, Aletra TJ, Georgoulias V. | Eur J Cancer. 2002 Mar.38(4):574-7. doi: 10.1016/s0959-8049(01)00401-4.
PMID: 11872352 |
| 5 | Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. | Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V. | J Clin Oncol.2002 Aug 15.20(16):3404-12.
doi: 10.1200/JCO.2002.08.135. PMID: 12177100 |
| 6 | Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. | Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis Ch, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulias V. | Oncology.2002.62(2):103-9.
doi: 10.1159/000048254. PMID: 11914594 |
| 7 | Adjuvant systemic therapy protocol for Dukes’ B2 and C resectable colon carcinoma. | Gennatas C, Mouratidou D, Androulakis G, Georgoulias V, Tsavaris N, Philippakis M, Michailakis E, Kalofonos C, Mpesmpeas S, Katsos J, Tsitoura M, Retalis G, Mallas E, Voros D, Andreadis C, Hatzistylianos G, Pisiotis C, Kamilarios D, Kakoliris S, Komporozos V, Kannas D, Legakis N, Mpatakis T, Ntamtsios J, Papaevangelou E, Peros G, Photopoulos A, Pouli A, Prigouris S, Samanidis L, Sakellariou V, Smyrniotis V, Polymeneas G, Vasiliou J, Athanasiou A, Papadimitriou J. | Tumori.2002 Jan-Feb;88(1):32-6
PMID: 12004847 |
| 8 | Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. | Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulias V; Greek Colorectal Cooperative Oncology Group. | Am J Clin Oncol. 2002 Feb.25(1):65-70.
doi: 10.1097/00000421-200202000-00014. PMID: 11823700 |
| 9 | Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). | Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulias V. | Am J Clin Oncol. 2002 Dec.25(6):627-31.
doi: 10.1097/00000421-200212000-00021. PMID: 12478014 Clinical Trial. |
| 10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. | Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V. | J Clin Oncol. 2002 Jun 1.20(11):2651-7. doi: 10.1200/JCO.2002.08.015.
PMID: 12039926 Clinical Trial. |
| 11 | A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. | Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N,Georgoulias V. | Anticancer Res. 2002 May-Jun.22(3):1891-6.
PMID: 12168889 |
| 12 | A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. | Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V. | Anticancer Res. 2002 Nov-Dec.22(6B):3743-8.
PMID: 12552987 Clinical Trial. |
| 13 | Docetaxel (taxotere) in the treatment of non-small cell lung cancer. | Georgoulias V. | Curr Med Chem. 2002 Apr.9(8):869-77. doi: 10.2174/0929867024606812.
PMID: 11966449 |
| 14 | Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. | Georgoulias V. | Lung Cancer.2002Dec.38 Suppl 3:S61-6.
doi: 10.1016/s0169-5002(02)00272-6. PMID: 12468149 |
| 15 | Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. | Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V; Hellenic Oncology Research Group. | Lung Cancer. 2002 Oct.38(1):59-63.
doi: 10.1016/s0169-5002(02)00149-6. PMID: 12367794 |
| 16 | A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. | Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V. | Anticancer Res. 2003 Jan-Feb.23(1B):785-91.
PMID: 12680184 |
| 17 | A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. | Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M,Georgoulias V. | Ann Oncol. 2003 Feb.14(2):304-12.
doi: 10.1093/annonc/mdg063. PMID: 12562660 |
| 18 | Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. | De Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. | Anticancer Res. 2003 May-Jun.23(3C):3019-27.
PMID: 12926156 |
| 19 | A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. | Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N. | Ann Oncol. 2003 Mar.14(3):433-40. doi: 10.1093/annonc/mdg111.
PMID: 12598350 |
| 20 | Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript. | Angelopoulou K, Spiropoulou T, Stathopoulou A, Dimitroulopoulos D, Malamos N,Georgoulias V, Paraskevas E, Lianidou ES. | Anticancer Res. 2003.
PMID: 14981931 |
| 21 | Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. | Agelaki S, Karyda E, Kouroussis Ch, Ardavanis A, Kalbakis K, Malas K, Malamos N, Alexopoulos A, Tselepatiotis E, Georgoulias V. | Oncology. 2003.64(4):477-8.
doi: 10.1159/000070312. PMID: 12759550 |
| 22 | Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. | Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E,Georgoulias V. | Anticancer Res. 2003 Mar-Apr.23(2C):1883-90.
PMID: 12820473 |
| 23 | Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. | Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V. | Ann Oncol. 2003 Jun.14(6):849-55.
doi: 10.1093/annonc/mdg259. PMID: 12796021 |
| 24 | Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. | Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D,Georgoulias V, Lianidou ES. | Clin Cancer Res. 2003 Nov 1.9(14):5145-51.
PMID: 14613993 |
| 25 | Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. | Mavroudis D, Alexopoulos A, Malamos N, Ardavanis A, Kandylis C, Stavrinidis E, Kouroussis Ch, Agelaki S, Androulakis N, Bozionelou V, Georgoulias V. | Oncology. 2003.64(3):207-12.
doi: 10.1159/000069306. PMID: 12697959 |
| 26 | Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. | Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. | Ann Oncol. 2003.14 Suppl 2:ii25-9.
doi: 10.1093/annonc/mdg725. PMID: 12810454 |
| 27 | Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. | Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. | Int J Radiat Oncol Biol Phys. 2003 Aug 1.56(5):1284-7.
doi: 10.1016/s0360-3016(03)00275-x. PMID: 12873672 |
| 28 | Salmonella enterica pneumonia in a patient with lung cancer. | Samonis G, Maraki S, Kouroussis C, Mavroudis D, Georgoulias V. | J Clin Microbiol. 2003 Dec.41(12):5820-2.
doi: 10.1128/JCM.41.12.58205822.2003. PMID: 14662992 |
| 29 | Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. | Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A, Agelidou M, Toumbis M, Tzannes S, Pavlakou G, Ziotopoulos P, Tzelepatiotis E, Samaras N. | Clin Lung Cancer. 2003 Mar.4(5):288-93.
doi: 10.3816/clc.2003.n.008. PMID: 14609446 |
| 30 | ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. | Pallis AG, Mavroudis D, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis IG, Georgoulias V. | Lung Cancer. 2003 Jun.40(3):301-7.
doi: 10.1016/s0169-5002(03)00079-5. PMID: 12781429 |
| 31 | Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. | de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. | Anticancer Drugs. 2003 Feb.14(2):103-10.
doi: 10.1097/00001813-200302000-00003. PMID: 12569296 |
| 32 | Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. | Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG,Georgoulias V; Greek Cooperative Group for Pancreatic Cancer. | Ann Oncol. 2003 Mar.14(3):388-94.
doi: 10.1093/annonc/mdg109. PMID: 12598343 |
| 33 | Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. | Mavroudis D, Pavlakou G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas E, Samonis G, Georgoulias V. | Lung Cancer. 2003 Jan.39(1):71-6.
doi: 10.1016/s0169-5002(02)00307-0. PMID: 12499097 |
| 34 | A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). | Kalofonos HP, Kourousis C, Karamouzis MV, Iconomou G, Tsiata E, Tzorzidis F, Megas P, Lambiris E, Georgoulias V. | Sarcoma. 2004.8(4):129-33.
doi: 10.1080/13577140400016705. PMID: 18521407 |
| 35 | Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. | Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. | Infection. 2004 Apr.32(2):65-71.
doi: 10.1007/s15010-004-3049-5. PMID: 15057569 |
| 36 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. | Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V. | Oncology. 2004.66(4):253-9.
doi: 10.1159/000078324. PMID: 15218291 Clinical Trial. |
| 37 | Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. | Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V. | Int J Cancer. 2004 Feb 10.108(4):620-7.
doi: 10.1002/ijc.11593. PMID: 14696130 |
| 38 | Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. | Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG). | Oncology. 2004.67(3-4):250-6.
doi: 10.1159/000081325. PMID: 15557786 |
| 39 | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. | Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. | J Clin Oncol. 2004 Oct 1.22(19):3893-901.
doi: 10.1200/JCO.2004.08.157. PMID: 15459210 |
| 40 | Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. | Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V. | Clin Cancer Res. 2004 Dec 15.10(24):8185-94.
doi: 10.1158/1078-0432.CCR-03-0094. PMID: 15623593 |
| 41 | Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. | Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A, Georgoulias V. | Ann Oncol. 2004 Aug.15(8):1204-9.
doi: 10.1093/annonc/mdh312. PMID: 15277259 Clinical Trial. |
| 42 | Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. | Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P, Christofilakis C, Ziras N, Alegakis A. | J Clin Oncol. 2004 Jul 1.22(13):2602-9.
doi: 10.1200/JCO.2004.11.004. PMID: 15226327 |
| 43 | Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. | Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I; Lung Cancer Committee of the Hellenic Oncology Research Group. | Br J Cancer. 2004 Aug 2.91(3):482-8.
doi: 10.1038/sj.bjc.6602010. PMID: 15238986 |
| 44 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. | Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V. | Ann Oncol. 2004 Feb.15(2):224-9.
doi: 10.1093/annonc/mdh065. PMID: 14760113 Clinical Trial. |
| 45 | A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. | Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. | Lung Cancer. 2004 Mar.43(3):329-33. doi: 10.1016/j.lungcan.2003.08.031.
PMID: 15165092 Clinical Trial. |
| 46 | A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. | Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V; Lung Cancer Subgroup, Hellenic Oncology Research Group. | Oncology. 2004.66(3):192-6.
doi: 10.1159/000077994. PMID: 15218309 Clinical Trial. |
| 47 | A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors. | Souglakos J, Kakolyris S, Vardakis N, Androulakis N, Mavroudis D, Vamvakas L, Kouroussis C, Agelaki S, Saridaki Z, Georgoulias V. | Cancer Invest. 2005.23(6):505-10.
doi: 10.1080/07357900500202713. PMID: 16203658 |
| 48 | Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. | Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA. | Cancer Chemother Pharmacol. 2005 Dec.56(6):615-22.
doi: 10.1007/s00280-005-1002-7. PMID: 16025289 |
| 49 | Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors. | Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki A, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V. | Oncology. 2005.69(3):202-7.
doi: 10.1159/000087908. PMID: 16127289 |
| 50 | Teaching cancer management to primary care health staff: the first experiences gained from Crete. | Lionis C, Samoutis G, Kouroussis C, Trigoni M, Georgoulias V. | J Cancer Educ. 2005 Spring.20(1):6-7.
doi: 10.1207/s15430154jce2001_4. PMID: 15876173 |
| 51 | Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status. | Tsakountakis N, Sanidas E, Stathopoulos E, Kafousi M, Anogiannaki N,Georgoulias V, Tsiftsis DD. | BMC Womens Health. 2005 Feb 4.5(1):1.
doi: 10.1186/1472-6874-5-1. PMID: 15694000 |
| 52 | Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. | Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V. | Ann Oncol. 2005 Feb.16(2):240-6.
doi: 10.1093/annonc/mdi043. PMID: 15668277 |
| 53 | Capecitabine as adjuvant treatment for stage III colon cancer. | Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. | N Engl J Med. 2005 Jun 30.352(26):2696-704.
doi: 10.1056/NEJMoa043116. PMID: 15987918 Clinical Trial. |
| 54 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. | Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V. | Oncology. 2005.69(5):384-90.
doi: 10.1159/000089992. PMID: 16319509 Clinical Trial. |
| 55 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. | Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. | J BUON. 2005 Jan-Mar.10(1):47-52.
PMID: 17335131 |
| 56 | Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. | Polyzos A, Syrigos K, Stergiou J, Panopoulos C, Potamianou A, Vamvakas L,Georgoulias V. | Cancer Chemother Pharmacol. 2005 May.55(5):466-70.
doi: 10.1007/s00280-004-0912-0. PMID: 15660272 |
| 57 | Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. | Agelaki S, Georgoulias V. | Expert Opin Emerg Drugs. 2005 Nov.10(4):855-74.
doi: 10.1517/14728214.10.4.855. PMID: 16262567 |
| 58 | Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. | Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinos V, Zachariadis E, Boukovinas I, Agelidou A, Kentepozidis N, Ignatiadis M, Vossos A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG). | Lung Cancer.2005 Oct.50(1):115-22.
doi: 10.1016/j.lungcan.2005.05.004. PMID: 15993981
|
| 59 | NSCLC–platinum or not. | Androulakis N, Georgoulias V. | Lung Cancer. 2005 Mar.47(3):381-3. doi: 10.1016/j.lungcan.2004.11.010. PMID: 15713521 |
| 60 | Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. | Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D. | Br J Cancer. 2005 Oct 3.93(7):763-9.
doi: 10.1038/sj.bjc.6602748. PMID: 16175189 |
| 61 | Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. | Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. | J Clin Oncol. 2005 May 1.23(13):2937-45.
doi: 10.1200/JCO.2005.04.016. PMID: 15728228 Clinical Trial. |
| 62 | Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. | Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K, Georgoulias V. | Anticancer Res. 2005 Sep-Oct.25(5):3559-64.
PMID: 16101180 |
| 63 | Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. | Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A. | Oncology. 2005.69(4):348-53.
doi: 10.1159/000089767. PMID: 16293974 |
| 64 | Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study. | Rapti A, Agelidou A, Stergiou I, Agelidou M, Nikolakopoulos I, Varthalitis J, Kalykaki A, Chainis K, Tzanakis N, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG). | Lung Cancer. 2005 Aug.49(2):241-4.
doi: 10.1016/j.lungcan.2005.01.003. PMID: 16022918 |
| 65 | Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. | Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J,Georgoulias V. | Clin Lung Cancer. 2005 Nov.7(3):183-9.
doi: 10.3816/CLC.2005.n.034. PMID: 16354313 |
| 66 | A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors. | Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, Mavroudis D, Georgoulias V. | Oncology. 2006.71(5-6):347-53.
doi: 10.1159/000107794. PMID: 17785992 |
| 67 | A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. | Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karampeazis A, Mavroudis D, Georgoulias V. | Oncology. 2006.71(3-4):197-203.
doi: 10.1159/000106069. PMID: 17641541 Clinical Trial. |
| 68 | A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors. | Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulias V, Mavroudis D. | Oncology. 2006.71(3-4):190-6.
doi: 10.1159/000106068. PMID: 17641537 Clinical Trial. |
| 69 | A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. | Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V. | Oncology. 2006.70(4):306-14.
doi: 10.1159/000096252. PMID: 17047402 |
| 70 | Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. | Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, Marselos M. | Anticancer Drugs. 2006 Nov.17(10):1185-91.
doi: 10.1097/01.cad.0000236303.97467.49.PMID: 17075318 Clinical Trial. |
| 71 | Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. | Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. | Eur J Nucl Med Mol Imaging. 2006 Oct.33(10):1115-22.
doi: 10.1007/s00259-006-0110-x. PMID: 16763820 |
| 72 | Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. | Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. | Eur J Nucl Med Mol Imaging. 2006 Apr.33(4):460-6.
doi: 10.1007/s00259-005-0006-1. PMID: 16437218 Clinical Trial. |
| 73 | Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. | Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulias V. | Oncology. 2006.70(4):280-4.
doi: 10.1159/000096249. PMID: 17047399 |
| 74 | Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. | Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, Mavroudis D, Georgoulias V. | Ann Oncol. 2006 Nov.17(11):1687-92.
doi: 10.1093/annonc/mdl286. PMID: 16968872 |
| 75 | A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. | Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N,Georgoulias V, Lianidou ES. | Int J Cancer. 2006 Oct 1.119(7):1654-9.
doi: 10.1002/ijc.22017. PMID: 16708381 |
| 76 | Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. | Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V. | Breast Cancer Res. 2006.8(4):R36.
doi: 10.1186/bcr1516. PMID: 16846533 |
| 77 | Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. | Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES. | Clin Biochem. 2006 Sep.39(9):879-87.
doi: 10.1016/j.clinbiochem.2006.06.009. PMID: 16925986 |
| 78 | HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. | Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, Mavroudis D, Georgoulias V, Lianidou ES. | Clin Biochem. 2006 Sep.39(9):942-6.
doi: 10.1016/j.clinbiochem.2006.06.001. PMID: 16916505 |
| 79 | Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. | Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. | Cancer Chemother Pharmacol. 2006 Dec.58(6):742-8.
doi: 10.1007/s00280-006-0236-3. PMID: 16718470 |
| 80 | Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. | Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D. | J Clin Oncol. 2006 Aug 10.24(23):3756-62.
doi: 10.1200/JCO.2005.04.5948. PMID: 16769987 |
| 81 | Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. | Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, Tselepatiotis E, Giassas S, Mavroudis D, Amarantidis K, Georgoulias V. | Oncology. 2006.70(4):273-9.
doi: 10.1159/000096248. PMID: 17047398 Clinical Trial. |
| 82 | Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. | Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulias V, Battelli N, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzelka L; Navelbine Herceptin Project. | Br J Cancer. 2006 Oct 9;95(7):788-93.
doi: 10.1038/sj.bjc.6603351. PMID: 16969343 |
| 83 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). | Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D,Georgoulias V. | Br J Cancer. 2006 Mar 27;94(6):798-805.
doi: 10.1038/sj.bjc.6603011. PMID: 16508637 |
| 84 | Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. | Ziras N, Potamianou A, Varthalitis I, Syrigos K, Tsousis S, Boukovinas I, Tselepatiotis E, Christofillakis C, Georgoulias V. | Oncology. 2006;70(2):106-14.
doi: 10.1159/000092956. PMID: 16645323 |
| 85 | VEGF expression in the colorectal adenoma-carcinoma sequence. | Kaklamanis L, Trichas M, Amarantidis K, Spathari N, Micheli A, Karayiannakis A, Chatzaki E, Georgoulias V, Kakolyris S. | Oncol Res. 2006;15(9):445-51.
PMID: 16555551 |
| 86 | A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. | Pallis AG, Agelidou A, Papakotoulas P, Tsaroucha A, Agelidou M, Agelaki S, Androulakis N, Vamvakas L, Gerogianni A, Kotsakis A, Kentepozidis N, Georgoulias V. | Lung Cancer. 2006 May;52(2):165-71.
doi: 10.1016/j.lungcan.2006.01.005. PMID: 16563559 |
| 87 | A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. | Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V; Lung Cancer Group of the Hellenic Oncology Research Group. | Clin Lung Cancer. 2006 Jul;8(1):49-55. doi: 10.3816/clc.2006.n.033.
PMID: 16870046 |
| 88 | Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. | Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K, Georgoulias V. | Lung Cancer. 2006 Dec;54(3):347-52.
doi: 10.1016/j.lungcan.2006.09.001. PMID: 17030075 |
| 89 | Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. | Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG. | Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):823-30.
doi: 10.1007/s00259-005-0063-5. PMID: 16570185 |
| 90 | Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. | Makrantonakis P, Ziotopoulos P, Agelidou A, Polyzos A, Ziras A, Chandrinos V, Vossos A, Kalykaki A, Androulakis N, Geroyianni A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group. | Lung Cancer. 2006 Jul;53(1):85-90.
doi: 10.1016/j.lungcan.2006.02.008. PMID: 16720058 |
| 91 | Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. | de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulias V, Tsiftsis DD. | Eur J Surg Oncol. 2006 Aug;32(6):666-70.
doi: 10.1016/j.ejso.2006.03.008. PMID: 16618534 |
| 92 | A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. | Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, Vamvakas L, Kotsakis A, Potamianou A, Georgoulias V. | Oncology. 2006;71(3-4):159-63.
doi: 10.1159/000106064. PMID: 17646699 |
| 93 | A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. | Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. | Br J Cancer. 2006 Sep 4;95(5):587-92.
doi: 10.1038/sj.bjc.6603301. PMID: 16909140 |
| 94 | Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma. | Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A,Georgoulias V. | Lung Cancer. 2006 Jul;53(1):59-65.
doi: 10.1016/j.lungcan.2006.03.011. PMID: 16716447 |
| 95 | A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. | Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D. | Br J Cancer. 2007 Jul 2;97(1):43-9.
doi: 10.1038/sj.bjc.6603832. PMID: 17551496 |
| 96 | Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. | Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C. | Cell Physiol Biochem. 2007;20(6):977-86.
doi: 10.1159/000110458. PMID: 17982280 |
| 97 | Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. | Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, Tsiftsis DD, Theodoropoulos PA. | Ann Surg Oncol. 2007 Mar;14(3):1220-8.
doi: 10.1245/s10434-006-9305-4. PMID: 17206477 |
| 98 | Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. | Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. | Ann Oncol. 2007 May;18(5):851-8.
doi: 10.1093/annonc/mdl502. PMID: 17301075 |
| 99 | Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. | Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D,Georgoulias V. | Ann Oncol. 2007 Oct;18(10):1623-31.
doi: 10.1093/annonc/mdm208. PMID: 17515404 |
| 100 | Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. | Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D. | J Clin Oncol. 2007 Nov 20;25(33):5194-202.
doi: 10.1200/JCO.2007.11.7762. PMID: 17954712 |
| 101 | Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. | Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D. | Clin Breast Cancer. 2007 Dec;7(11):883-9.
doi: 10.3816/CBC.2007.n.054. PMID: 18269779 |
| 102 | Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. | Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. | Mol Med. 2007 Jan-Feb;13(1-2):79-88.
doi: 10.2119/2006-00083.Kallergi. PMID: 17515959 |
| 103 | ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. | Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, Revela I, Athanasiou A, Mavroudis D, Georgoulias V. | Int J Cardiol. 2007 Nov 30;122(3):195-201.
doi: 10.1016/j.ijcard.2006.11.076. PMID: 17289172 |
| 104 | Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. | Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group. | Eur J Cancer. 2007 Sep;43(14):2037-45.
doi: 10.1016/j.ejca.2007.07.017. PMID: 17766104 |
| 105 | Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. | Maniadakis N, Pallis A, Fragoulakis V, Prezerakos P, Georgoulias V. | Curr Med Res Opin. 2007 Sep;23(9):2251-7.
doi: 10.1185/030079907X223765. PMID: 17706002 |
| 106 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. | Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulias V, Mavroudis D, Souglakos J. | BMC Cancer. 2007 May 30;7:91.
doi: 10.1186/1471-2407-7-91. PMID: 17537235 |
| 107 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. | Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kourousis C, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. | Dig Dis. 2007;25(1):100-5.
doi: 10.1159/000099177. PMID: 17384515 Clinical Trial. |
| 108 | Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. | Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V. | Ann Oncol. 2007 Feb;18(2):305-10.
doi: 10.1093/annonc/mdl392. PMID: 17079693 |
| 109 | Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract. | Gkioulbasanis I, Souglakos J, Vardakis N, Kotsakis A, Saridaki Z, Kentepozidis N, Polyzos A, Giassas S, Ignatiadis M, Bozionelou V, Christophylakis C, Georgoulias V. | J BUON. 2007 Apr-Jun;12(2):197-202.
PMID: 17600872 |
| 110 | ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. | Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, Georgoulias V. | Br J Cancer. 2007 Dec 3;97(11):1560-6.
doi: 10.1038/sj.bjc.6604068. PMID: 18000506 |
| 111 | Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. | Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. | J Thorac Oncol. 2007 Oct;2(10):939-46.
doi: 10.1097/JTO.0b013e318153fa2b. PMID: 17909357 |
| 112 | Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. | Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. | Lung Cancer. 2007 Nov;58(2):275-81. doi: 10.1016/j.lungcan.2007.06.012. PMID: 17688969
Clinical Trial. |
| 113 | Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. | Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, Mavroudis D, Georgoulias V. | Lung Cancer. 2007 Jan;55(1):101-7.
doi: 10.1016/j.lungcan.2006.08.019. PMID: 17049673 |
| 114 | Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. | Koutsopoulos AV, Mavroudis D, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulias V, Stathopoulos EN. | Lung Cancer. 2007 Aug;57(2):193-200.
doi: 10.1016/j.lungcan.2007.03.009. PMID: 17442448 |
| 115 | Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. | Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D. | J Clin Oncol. 2007 Jul 1;25(19):2727-34. doi: 10.1200/JCO.2006.10.3465.
PMID: 17602077 Clinical Trial. |
| 116 | A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. | Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2008 Aug;62(3):449-56.
doi: 10.1007/s00280-007-0624-3. PMID: 17960381 |
| 117 | Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. | Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulias V, Mavroudis D. | Anticancer Res. 2008 Sep-Oct;28(5B):3019-25.
PMID: 19031950 |
| 118 | Micrometastatic disease in breast cancer: clinical implications. | Ignatiadis M, Georgoulias V, Mavroudis D. | Eur J Cancer. 2008 Dec;44(18):2726-36. doi: 10.1016/j.ejca.2008.09.033.
PMID: 19056036 |
| 119 | Paclitaxel and docetaxel in the treatment of breast cancer. | Saloustros E, Mavroudis D, Georgoulias V. | Expert Opin Pharmacother. 2008 Oct;9(15):2603-16.
doi: 10.1517/14656566.9.15.2603. PMID: 18803448 |
| 120 | Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. | Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. | Breast Cancer Res. 2008;10(5):R80.
doi: 10.1186/bcr2149. PMID: 18822183 |
| 121 | Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. | Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. | Clin Cancer Res. 2008 May 1;14(9):2593-600.
doi: 10.1158/1078-0432.CCR-07-4758. PMID: 18451221
|
| 122 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. | Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. | Oncology. 2008;74(1-2):31-6.
doi: 10.1159/000138977. PMID: 18544957 |
| 123 | Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. | Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R. | Br J Cancer. 2008 May 20;98(10):1710-5.
doi: 10.1038/sj.bjc.6604344. PMID: 18414411 |
| 124 | Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. | Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG). | Lung Cancer. 2008 Dec;62(3):356-63.
doi: 10.1016/j.lungcan.2008.03.030. PMID: 18501466 |
| 125 | Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. | Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A. | Br J Cancer. 2008 Sep 16;99(6):923-9. doi: 10.1038/sj.bjc.6604629.
PMID: 19238633 |
| 126 | Docetaxel in the treatment of advanced non-small-cell lung cancer. | Saloustros E, Georgoulias V. | Expert Rev Anticancer Ther. 2008 Aug;8(8):1207-22.
doi: 10.1586/14737140.8.8.1207. PMID: 18699760 |
| 127 | Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. | Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. | Lung Cancer. 2008 Jan;59(1):57-63.
doi: 10.1016/j.lungcan.2007.07.021. PMID: 17765354 |
| 128 | Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. | Pallis AG, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, Agelidou M, Pavlakou G, Chandrinos V, Kakolyris S, Christophyllakis C, Kentepozidis N, Giassas S, Androulakis N, Agelaki S, Georgoulias V. | J Thorac Oncol. 2008 May;3(5):505-10.
doi: 10.1097/JTO.0b013e31816b4b32. PMID: 18449003 |
| 129 | Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. | Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. | Clin Chem. 2008 Oct;54(10):1696-704.
doi: 10.1373/clinchem.2007.101741. PMID: 18719201 |
| 130 | Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. | Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J. | PLoS One. 2008;3(11):e3695.
doi: 10.1371/journal.pone.0003695. PMID: 19002265 |
| 131 | Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. | Anticancer Res. 2008 Jan-Feb;28(1B):495-500.
PMID: 18383891 |
| 132 | Present treatment and future expectations in advanced pancreatic cancer. | Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V. | Anticancer Res. 2008 Mar-Apr;28(2B):1303-8.
PMID: 18505070 |
| 133 | A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. | Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2009 Dec;65(1):121-8.
doi: 10.1007/s00280-009-1013-x. PMID: 19415279 |
| 134 | A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. | Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A,Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2009 Sep;64(4):785-91.
doi: 10.1007/s00280-009-0928-6 PMID: 19159931 |
| 135 | Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. | Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. | Cancer Biol Ther. 2009 Aug;8(15):1470-7.
doi: 10.4161/cbt.8.15.8939. PMID: 19483462 |
| 136 | Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. | Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D. | J Clin Oncol. 2009 May 1;27(13):2177-84.
doi: 10.1200/JCO.2008.18.0497. PMID: 19332733 |
| 137 | Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. | Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V. | Br J Cancer. 2009 Aug 18;101(4):589-97.
doi: 10.1038/sj.bjc.6605183. PMID: 19623181 |
| 138 | Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. | Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. | Breast Cancer Res Treat. 2009 Oct;117(3):525-34.
doi: 10.1007/s10549-008-0239-3. PMID: 19016323 |
| 139 | Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. | Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES,Georgoulias V, Mavroudis D, Agelaki S. | Breast Cancer Res. 2009;11(6):R84.
doi: 10.1186/bcr2452. PMID: 19919679 |
| 140 | Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. | Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES. | Ann Oncol. 2009 Jun;20(6):1020-5.
doi: 10.1093/annonc/mdn733. PMID: 19150938 |
| 141 | Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. | Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D,Georgoulias V, Lianidou ES. | Int J Cancer. 2009 Dec 15;125(12):2887-92.
doi: 10.1002/ijc.24686. PMID: 19551853 |
| 142 | Prognostic significance of RASSF1A promoter methylation in operable breast cancer. | Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. | Clin Biochem. 2009 Jul;42(10-11):970-5.
doi: 10.1016/j.clinbiochem.2009.04.003 PMID: 19374895 |
| 143 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. | Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. | Br J Cancer. 2009 Aug 4;101(3):465-72. doi: 10.1038/sj.bjc.6605164.
PMID: 19603024 |
| 144 | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. | Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators. | Ann Oncol. 2009 Nov;20(11):1842-7.
doi: 10.1093/annonc/mdp233. PMID: 19406901 |
| 145 | Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. | Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D,Georgoulias V. | Lung Cancer. 2009 Jan;63(1):77-82.
doi: 10.1016/j.lungcan.2008.04.006. PMID: 18508158 |
| 146 | Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. | Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J. | Clin Cancer Res. 2009 Jun 1;15(11):3827-33.
doi: 10.1158/1078-0432.CCR-08-3027. PMID: 19435835 |
| 147 | Advanced non-small-cell lung cancer in the elderly. | Vamvakas L, Saloustros E, Karampeazis A, Georgoulias V. | Clin Lung Cancer. 2009 May;10(3):158-67.
doi: 10.3816/CLC.2009.n.022. PMID: 19443335 |
| 148 | Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. | Kouroussis C, Vamvakas L, Vardakis N, Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N, Giassas S, Georgoulias V. | Oncology. 2009;76(2):112-7.
doi: 10.1159/000192586. PMID: 19142045 |
| 149 | DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. | Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D. | Clin Lung Cancer. 2009 Mar;10(2):118-23.
doi: 10.3816/CLC.2009.n.015. PMID: 19362955 |
| 150 | Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. | Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. | J Clin Oncol. 2009 Apr 10;27(11):1836-43.
doi: 10.1200/JCO.2008.17.5844. PMID: 19273711 |
| 151 | A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. | Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, Rapti A, Chandrinos V, Christophyllakis C, Georgoulias V. | Lung Cancer. 2009 Aug;65(2):187-91.
doi: 10.1016/j.lungcan.2008.11.002. PMID: 19100647 |
| 152 | A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. | Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N. | Oncology. 2010;78(5-6):356-60.
doi: 10.1159/000320462. PMID: 20798557 |
| 153 | Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. | Saloustros E, Androulakis N, Vamvakas L, Mavroudis D, Georgoulias V. | Case Rep Oncol (karger). 2010 Oct 12;3(3):368-71.
doi: 10.1159/000321630. PMID: 21537380 |
| 154 | PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. | Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. | J Mol Diagn. 2010 Sep;12(5):697-704.
doi: 10.2353/jmoldx.2010.100008. PMID: 20616362 |
| 155 | Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. | Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. | Breast Cancer Res Treat. 2010 Jul;122(1):1-7.
doi: 10.1007/s10549-009-0727-0. PMID: 20063120 |
| 156 | Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. | Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D,Georgoulias V. | Cancer Lett. 2010 Feb 1;288(1):99-106.
doi: 10.1016/j.canlet.2009.06.027. PMID: 19619935 |
| 157 | Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. | Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, Casazza G. | J Natl Compr Canc Netw. 2010 Mar;8(3):279-86.
doi: 10.6004/jnccn.2010.0020. PMID: 20202461 |
| 158 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). | Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. | Breast Cancer Res Treat. 2010 Jan;119(1):95-104.
doi: 10.1007/s10549-009-0468-0. PMID: 19636702 |
| 159 | Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. | Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. | Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7.
doi: 10.1016/j.critrevonc.2009.03.006. PMID: 19369092 |
| 160 | Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. | Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. | Gynecol Oncol. 2010 Apr;117(1):139-45.
doi: 10.1016/j.ygyno.2009.12.001. PMID: 20061004 |
| 161 | Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. | Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. | Breast J. 2010 May-Jun;16(3):245-51. doi: 10.1111/j.15244741.2010.00905.x.
PMID: 20210799 |
| 162 | Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. | Karachaliou N, Saloustros E, Vamvakas L, Mavroudis D, Georgoulias V. | Ann Oncol. 2010 Aug;21(8):1729-1730.
doi: 10.1093/annonc/mdq328 PMID: 20601370 |
| 163 | Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. | Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N,Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group. | Ann Oncol. 2010 Jan;21(1):48-54.
doi: 10.1093/annonc/mdp498. PMID: 19906761 |
| 164 | BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. | Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J. | Br J Cancer. 2010 Jun 8;102(12):1762-8.
doi: 10.1038/sj.bjc.6605694. PMID: 20485284 |
| 165 | Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). | Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A, Kouroussis Ch, Ziras N, Kalbakis K, Georgoulias V, Souglakos J. | Crit Rev Oncol Hematol. 2010 Oct;76(1):61-70.
doi: 10.1016/j.critrevonc.2009.08.003. PMID: 19729318 |
| 166 | Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. | Saridaki Z, Georgoulias V, Souglakos J. | World J Gastroenterol. 2010 Mar 14;16(10):1177-87.
doi: 10.3748/wjg.v16.i10.1177. PMID: 20222160 |
| 167 | Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. | Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, Georgoulias V, Mavroudis D. | J Neurooncol. 2010 Apr;97(2):291-4.
doi: 10.1007/s11060-009-0022-2. PMID: 19798470 |
| 168 | A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. | Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V. | Cancer Chemother Pharmacol. 2011 Jun;67(6):1239-45.
doi: 10.1007/s00280-010-1415-9. PMID: 20697712 |
| 169 | A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. | Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. | BMC Cancer. 2010 Nov 19;10:633.
doi: 10.1186/1471-2407-10-633. PMID: 21092076 |
| 170 | Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. | Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. | Eur J Cancer. 2010 Mar;46(4):735-43.
doi: 10.1016/j.ejca.2009.12.013. PMID: 20045311 |
| 171 | Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. | Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V, Voutsina A. | Lung Cancer. 2010 Jul;69(1):110-5.
doi: 10.1016/j.lungcan.2009.09.010. PMID: 19854533 |
| 172 | Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. | Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. | Ann Oncol. 2010 Jul;21(7):1462-1467.
doi: 10.1093/annonc/mdp551. PMID: 20019086 |
| 173 | Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group. | Agelaki S, Hatzidaki D, Kotsakis A, Papakotoulas P, Polyzos A, Ziras N, Gioulbasanis I, Karampeazis A, Agelidou A, Tsiafaki X, Chandrinos V, Lerikou M, Georgoulias V. | Oncology. 2010;78(3-4):229-36.
doi: 10.1159/000315729. PMID: 20523083 Clinical Trial. |
| 174 | Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. | Kotsakis A, Georgoulias V. | Expert Opin Pharmacother. 2010 Oct;11(14):2363-89.
doi: 10.1517/14656566.2010.498581. PMID: 20586711 |
| 175 | Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. | Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S. | Lung Cancer. 2010 Jun;68(3):450-4.
doi: 10.1016/j.lungcan.2009.08.012. PMID: 19783319 Clinical Trial. |
| 176 | Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. | Saloustros E, Tryfonidis K, Georgoulias V. | Expert Opin Pharmacother. 2011 Apr;12(6):851-63.
doi: 10.1517/14656566.2011.541155. PMID: 21254862 |
| 177 | Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients. | Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. | J Immunother. 2011 Nov-Dec;34(9):641-50.
doi: 10.1097/CJI.0b013e31823284a6. PMID: 21989412 |
| 178 | Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. | Daskalakis M, Mavroudis D, Sanidas E, Apostolaki S, Askoxylakis I, de Bree E,Georgoulias V, Melissas J. | Eur J Surg Oncol. 2011 May;37(5):404-10.
doi: 10.1016/j.ejso.2011.02.003. PMID: 21376504 |
| 179 | Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. | Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D. | Breast Cancer Res. 2011 Jun 10;13(3):R60.
doi: 10.1186/bcr2897. PMID: 21663668 |
| 180 | DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. | Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES. | Clin Chem. 2011 Aug;57(8):1169-77. doi: 10.1373/clinchem.2011.165902.
PMID: 21700955 |
| 181 | Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. | Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. | Breast Cancer Res. 2011 Jun 10;13(3):R59.
doi: 10.1186/bcr2896. PMID: 21663619 |
| 182 | Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. | Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E. | BMC Cancer. 2011 Oct 4;11:422.
doi: 10.1186/1471-2407-11-422. PMID: 21967632 |
| 183 | Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. | Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D. | J BUON. 2011 Apr-Jun;16(2):215-8.
PMID: 21766488 |
| 184 | Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. | Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. | Clin Chem. 2011 Mar;57(3):421-30.
doi: 10.1373/clinchem.2010.154328. PMID: 21245367 |
| 185 | Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. | Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2011 Jul;68(1):217-23.
doi: 10.1007/s00280-010-1475-x. PMID: 20922389 |
| 186 | Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. | Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V. | Breast (Elsevier). 2011 Dec;20(6):485-90.
doi: 10.1016/j.breast.2011.06.009. PMID: 21784637 |
| 187 | Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. | Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. | PLoS One. 2011 Jan 20;6(1):e15980.
doi: 10.1371/journal.pone.0015980. PMID: 21283802 |
| 188 | Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer. | Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J. | Clin Cancer Res. 2011 Jan 1;17(1):165-73.
doi: 10.1158/1078-0432.CCR-10-0565. PMID: 21071514 |
| 189 | Hypofractionated accelerated CT-guided interstitial ¹⁹²Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. | Tselis N, Ratka M, Vogt HG, Kolotas C, Baghi M, Baltas D, Fountzilas G,Georgoulias V, Ackermann H, Zamboglou N. | Radiother Oncol. 2011 Jan;98(1):57-62.
doi: 10.1016/j.radonc.2010.10.025. PMID: 21129799 |
| 190 | Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. | Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulias V, Mavroudis D. | Ann Oncol. 2011 Apr;22(4):835-841.
doi: 10.1093/annonc/mdq440. PMID: 20937647 |
| 191 | Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. | Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, Mavroudis D, Georgoulias V. | Lung Cancer. 2011 Dec;74(3):516-20.
doi: 10.1016/j.lungcan.2011.05.009. PMID: 21632145 |
| 192 | A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. | Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V. | Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22.
doi: 10.1007/s00280-010-1508-5. PMID: 21069335 Clinical Trial. |
| 193 | A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. | Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V. | Cancer Chemother Pharmacol. 2011 Jun;67(6):1239-45.
doi: 10.1007/s00280-010-1415-9 PMID: 20697712 |
| 194 | Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. | Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, Maragouli E, Georgoulias V, Papandreou CN. | Oncology. 2011;81(2):113-8.
doi: 10.1159/000331685. PMID: 21986483 |
| 195 | Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. | Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. | Br J Cancer2011 Jan 18;104(2):316-23.
doi: 10.1038/sj.bjc.6606027. PMID: 21157449 |
| 196 | Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a hellenic oncology research group randomized phase III study. | Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. | Clin Lung Cancer. 2011 May;12(3):155-60.
doi: 10.1016/j.cllc.2011.03.015. PMID: 21663857 |
| 197 | Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. | Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V. | Ann Oncol. 2011 Nov;22(11):2448-2455.
doi: 10.1093/annonc/mdq772. PMID: 21393380 |
| 198 | How close are we to customizing chemotherapy in early non-small cell lung cancer? | Ioannidis G, Georgoulias V, Souglakos J. | Ther Adv Med Oncol. 2011 Jul;3(4):185-205.
doi: 10.1177/1758834011409973. PMID: 21904580 |
| 199 | Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. | Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S. | Clin Lung Cancer. 2011 Mar;12(2):100-5.
doi: 10.1016/j.cllc.2011.03.004. PMID: 21550556 |
| 200 | Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. | Spiliotaki M, Markomanolaki H, Mela M, Mavroudis D, Georgoulias V, Agelaki S. | Lung Cancer. 2011 Aug;73(2):158-65.
doi: 10.1016/j.lungcan.2010.11.010. PMID: 21190751 |
| 201 | Small cell ovarian cancer in adolescents: report of two cases and review of the literature. | Rovithi M, Pallis AG, Kalykaki A, Lagoudaki E, Giannikaki L, Stathopoulos EN, Relakis K, Georgoulias V. | Case Rep Med. 2011;2011:749516.
doi: 10.1155/2011/749516 PMID: 21738537 |
| 202 | Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. | Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V. | Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8.
doi: 10.1007/s00280-010-1329-6 PMID: 20428874 |
| 203 | Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. | Stylianou K, Lioudaki E, Papadimitraki E, Kokologiannakis G, Kroustalakis N, Liotsi C, Giannakakis K, Georgoulias V, Daphnis E. | Nephrol Dial Transplant. 2011 May;26(5):1742-5.
doi: 10.1093/ndt/gfr093. PMID: 21382992 |
| 204 | Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. | Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K, Georgoulias V. | Cancer Chemother Pharmacol. 2011 Jul;68(1):63-8.
doi: 10.1007/s00280-010-1427-5. PMID: 20830475 |
| 205 | A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. | Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES. | BMC Cancer. 2012 Oct 22;12:486.
doi: 10.1186/1471-2407-12-486. PMID: 23088560 |
| 206 | Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V. | Cancer Chemother Pharmacol. 2012 Feb;69(2):351-6.
doi: 10.1007/s00280-011-1694-9. PMID: 21748359 |
| 207 | Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. | Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D. | Ann Oncol. 2012 Feb;23(2):442-9.
doi: 10.1093/annonc/mdr396 PMID: 21873272 |
| 208 | Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. | Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D. | Cancer Immunol Immunother. 2012 Feb;61(2):157-168.
doi: 10.1007/s00262-011-1093-4. PMID: 21858533 |
| 209 | Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. | Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. | J Immunol Methods. 2012 Jul 31;381(1-2):14-22.
doi: 10.1016/j.jim.2012.04.004. PMID: 22522114 |
| 210 | Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. | Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V. | Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8.
doi: 10.1007/s00280-012-1896-9. PMID: 22660737 |
| 211 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. | Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76.
doi: 10.1007/s00280-012-1901-3. PMID: 22669571 |
| 212 | A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. | Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2012 May;69(5):1345-52.
doi: 10.1007/s00280-012-1824-z. PMID: 22349809 |
| 213 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. | Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D. | Ann Oncol. 2012 May;23(5):1164-1169.
doi: 10.1093/annonc/mdr405 PMID: 21937705 |
| 214 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. | Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2012 Jan;69(1):35-42.
doi: 10.1007/s00280-011-1663-3. PMID: 21590447 |
| 215 | Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. | Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V. | Br J Cancer. 2012 Jun 5;106(12):1917-25.
doi: 10.1038/bjc.2012.202. PMID: 22669159 |
| 216 | Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. | Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D. | Ann Oncol. 2012 Jul;23(7):1744-50.
doi: 10.1093/annonc/mds020. PMID: 22377561 |
| 217 | A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. | Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J. | Br J Cancer. 2012 Dec 4;107(12):1932-7.
doi: 10.1038/bjc.2012.509. PMID: 23169296 |
| 218 | Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). | Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A. | Br J Cancer. 2012 Jan 31;106(3):453-9.
doi: 10.1038/bjc.2011.594. PMID: 22240792 |
| 219 | Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. | Giannousi Z, Gioulbasanis I, Pallis AG, Xyrafas A, Dalliani D, Kalbakis K, Papadopoulos V, Mavroudis D, Georgoulias V, Papandreou CN. | Support Care Cancer. 2012 Aug;20(8):1823-9.
doi: 10.1007/s00520-011-1282-x. PMID: 21959842 |
| 220 | The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. | Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V. | Lung Cancer. 2012 Aug;77(2):383-8.
doi: 10.1016/j.lungcan.2012.04.008. PMID: 22551892 |
| 221 | A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. | Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V. | Clin Lung Cancer. 2012 Mar;13(2):129-35.
doi: 10.1016/j.cllc.2011.08.004. PMID: 22000696 |
| 222 | Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. | Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, Mavroudis D, Georgoulias V. | Nutr Cancer. 2012;64(1):41-7.
doi: 10.1080/01635581.2012.630157. PMID: 22098075 |
| 223 | ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. | Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. | J Thorac Oncol. 2012 Apr;7(4):663-71.
doi: 10.1097/JTO.0b013e318244bdd4. PMID: 22425915 |
| 224 | Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today’s standard of care. | Pallis AG, Georgoulias V. | Lung Cancer. 2012 Mar;75(3):269-74.
doi: 10.1016/j.lungcan.2011.09.010. PMID: 21996086 |
| 225 | Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. | Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold Ch, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC; Central European Cooperative Oncology Group (CECOG). | Ann Oncol. 2012 May;23(5):1223-1229.
doi: 10.1093/annonc/mdr381. PMID: 21940784 |
| 226 | Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. | Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V. | Lung Cancer. 2012 Jul;77(1):146-50.
doi: 10.1016/j.lungcan.2012.02.002. PMID: 22418242 |
| 227 | A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. | Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. | Breast (Elsevier). 2013 Dec;22(6):1171-7.
doi: 10.1016/j.breast.2013.08.017. PMID: 24091128 |
| 228 | Apoptotic circulating tumor cells in early and metastatic breast cancer patients. | Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulias V, Agelaki S. | Mol Cancer Ther. 2013 Sep;12(9):1886-95.
doi: 10.1158/1535-7163.MCT-12-1167 PMID: 23778153 |
| 229 | Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. | Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. | Mol Cancer Res. 2013 Oct;11(10):1248-57.
doi: 10.1158/1541-7786.MCR-13-0096. PMID: 23744981 |
| 230 | Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. | Lianidou ES, Mavroudis D, Georgoulias V. | Br J Cancer. 2013 Jun 25;108(12):2426-32.
doi: 10.1038/bjc.2013.265. PMID: 23756869
|
| 231 | CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. | Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N,Georgoulias V, Lianidou E. | Clin Biochem. 2013 Feb;46(3):235-40.
doi: 10.1016/j.clinbiochem.2012.09.015. PMID: 23006792 |
| 232 | Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. | Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V. | Br J Cancer. 2013 Feb 19;108(3):549-56.
doi: 10.1038/bjc.2012.597. PMID: 23329233 |
| 233 | PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. | Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. | J Mol Diagn. 2010 Sep;12(5):697-704.
doi: 10.2353/jmoldx.2010.100008. PMID: 20616362 |
| 234 | SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. | Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. | Clin Chem. 2013 Jan;59(1):270-9.
doi: 10.1373/clinchem.2012.191551 PMID: 23136251 |
| 235 | BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. | Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. | PLoS One. 2013 Dec 18;8(12):e84604.
doi: 10.1371/journal.pone.0084604. PMID: 24367680 |
| 236 | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. | Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. | Mod Pathol. 2013 Feb;26(2):302-13.
doi: 10.1038/modpathol.2012.150. PMID: 22936063 |
| 237 | Postoperative Treatment With Docetaxel, Cisplatin, and Capecitabine (DCX) and Chemoradiotherapy (CRT) With Capecitabine for Resected Gastric Adenocarcinoma. | Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulias V, Souglakos J. | Am J Clin Oncol. 2015 Feb;38(1):17-22.
doi: 10.1097/COC.0b013e3182893f13. PMID: 23563209 |
| 238 | A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. | Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C. | Clin Lung Cancer. 2013 Jul;14(4):461-5.
doi: 10.1016/j.cllc.2013.02.001. PMID: 23647738 |
| 239 | Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. | Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V. | Cancer Chemother Pharmacol. 2013 Mar;71(3):605-12.
doi: 10.1007/s00280-012-2037-1. PMID: 23338050 |
| 240 | Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. | Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D. | Lung Cancer. 2013 Nov;82(2):324-9.
doi: 10.1016/j.lungcan.2013.08.001. PMID: 23993732 |
| 241 | Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. | Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V. | Cancer. 2013 Aug 1;119(15):2754-64.
doi: 10.1002/cncr.28132. PMID: 23661337 |
| 242 | Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. | Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. | BMJ Open. 2013 Mar 13;3(3):e001802.
doi: 10.1136/bmjopen-2012-001802. PMID: 23485717 |
| 243 | A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. | Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V. | Cancer Chemother Pharmacol. 2013 Jul;72(1):45-51.
doi: 10.1007/s00280-013-2167-0. PMID: 23604531 |
| 244 | Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. | Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. | PLoS One. 2013 Sep 13;8(9):e74611.
doi: 10.1371/journal.pone.0074611. PMID: 24058603 |
| 245 | Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. | Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR,Georgoulias V, Lianidou ES. | Br J Cancer. 2014 Apr 15;110(8):2054-62.
doi: 10.1038/bjc.2014.104. PMID: 24642624 |
| 246 | Plasmablastic Lymphoma of the Breast in an Immunocompetent Patient: Long-lasting Complete Response Induced by Chemotherapy and Autologous Stem Cell Trasplantation. | Matikas A, Kanellis G, Papadimitriou C, Papadaki T, Kotsakis A, Dimopoulos MA,Georgoulias V. | Anticancer Res. 2014 Sep;34(9):5111-5
PMID: 25202100 |
| 247 | A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype. | Fostira F, Tsoukalas N, Konstantopoulou I, Georgoulias V, Christophyllakis C, Yannoukakos D. | Case Rep Genet. 2014;2014:875029.
doi: 10.1155/2014/875029. PMID: 24660075 |
| 248 | Detection of Circulating Cytokeratin-19 mRNA-Positive Cells in the Blood and the Mitotic Index of the Primary Tumor Have Independent Prognostic Value in Early Breast Cancer. | Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E, Mavroudis D. | Clin Breast Cancer. 2014 Dec;14(6):442-50.
doi: 10.1016/j.clbc.2014.04.001. PMID: 24958324 |
| 249 | Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. | Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V. | Cancer Chemother Pharmacol. 2014 Apr;73(4):685-93.
doi: 10.1007/s00280-014-2387-y. PMID: 24493157 |
| 250 | Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. | Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. | Clin Chem. 2014 Jan;60(1):197-205.
doi: 10.1373/clinchem.2013.210542. PMID: 24132943 |
| 251 | BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. | Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. | PLoS One. 2013 Dec 18;8(12):e84604.
doi: 10.1371/journal.pone.0084604. PMID: 24367680 |
| 252 | Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J. | BMC Cancer. 2014 Apr 22;14:277.
doi: 10.1186/1471-2407-14-277. PMID: 24755296 |
| 253 | KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer. | Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulias V, Voutsina A. | PLoS One. 2014 Aug 19;9(8):e104902.
doi: 10.1371/journal.pone.0104902 PMID: 25137394 |
| 254 | Prognostic and predictive significance of MSI in stages II/III colon cancer. | Saridaki Z, Souglakos J, Georgoulias V. | World J Gastroenterol. 2014 Jun 14;20(22):6809-14.
doi: 10.3748/wjg.v20.i22.6809. PMID: 24944470 |
| 255 | Lung cancer in the era of Greek economic crisis. | Saloustros E, Vichas G, Margiolaki A, Koumiotaki S, Androulakis N, Georgoulias V. | Lung Cancer.2014 Oct;86(1):112-3.
doi: 10.1016/j.lungcan.2014.07.016. PMID: 25130082 |
| 256 | A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. | Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V. | Lung Cancer. 2014 Oct;86(1):59-66.
doi: 10.1016/j.lungcan.2014.07.018. PMID: 25130084 |
| 257 | PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. | Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J. | Br J Cancer. 2014 Oct 28;111(9):1757-64.
doi: 10.1038/bjc.2014.492. PMID: 25233397 |
| 258 | Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. | Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian RG, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, Castellino SM, Lamovec J, Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulias V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WG, Clarke BA, Riazalhosseini Y, Hasselblatt M, Majewski J, Foulkes WD. | Nat Genet. 2014 May;46(5):438-43.
doi: 10.1038/ng.2931. PMID: 24658002 |
| 259 | Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG). | Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulias V. | Cancer Chemother Pharmacol. 2014 Apr;73(4):819-25.
doi: 10.1007/s00280-014-2411-2. PMID: 24531559 |
| 260 | Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V. | Cancer Chemother Pharmacol. 2014 Aug;74(2):333-40.
doi: 10.1007/s00280-014-2509-6. PMID: 24930058 |
| 261 | A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. | Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E. | Clin Chim Acta. 2015 Apr 15;444:303-9.
doi: 10.1016/j.cca.2015.02.035. PMID: 25727515 |
| 262 | A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. | Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E. | Clin Chim Acta. 2015 Apr 15;444:303-9.
doi: 10.1016/j.cca.2015.02.035. PMID: 25727515 |
| 263 | Metastasis-related miRNAs: a new way to differentiate patients with higher risk? | Markou A, Lianidou E, Georgoulias V. | Future Oncol. 2015;11(3):365-7.
doi: 10.2217/fon.14.294. PMID: 25675118 |
| 264 | Metastasis-related miRNAs: a new way to differentiate patients with higher risk? | Markou A, Lianidou E, Georgoulias V. | Future Oncol. 2015;11(3):365-7.
doi: 10.2217/fon.14.294. PMID: 25675118 |
| 265 | Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. | Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. | Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60.
doi: 10.1007/s00280-014-2628-0. PMID: 25398698 |
| 266 | Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). | Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. | Breast Cancer Res Treat. 2014 Dec;148(3):591-7.
doi: 10.1007/s10549-014-3202-5. PMID: 25399229 |
| 267 | Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. | Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D. | Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25.
doi: 10.1007/s00280-014-2598-2. PMID: 25344760 |
| 268 | Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. | Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V | PLoS One. 2015 Jun 17;10(6):e0123683.
doi: 10.1371/journal.pone.0123683. PMID: 26083256 |
| 269 | Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. | Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K,Georgoulias V, Agelaki S. | Breast Cancer Res. 2014 Nov 29;16(6):485.
doi: 10.1186/s13058-014-0485-8. PMID: 25432416 |
| 270 | Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. | Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V. | Breast Cancer Res. 2015 Aug 19;17(1):113.
doi: 10.1186/s13058-015-0624-x PMID: 26285572 |
| 271 | PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. | Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E. | Clin Cancer Res. 2014 Nov 15;20(22):5823-34.
doi: 10.1158/1078-0432.CCR-14-0149. PMID: 25398847 |
| 272 | Six versus twelve months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V | Ann Oncol. 2015 Jul;26(7):1333-40.
doi: 10.1093/annonc/mdv213. PMID: 25935793 |
| 273 | Six versus twelve months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V | Ann Oncol. 2015 Jul;26(7):1333-40.
doi: 10.1093/annonc/mdv213 PMID: 25935793 |
| 274 | The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. | Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. | Cancers (Basel). 2015 Mar 13;7(1):439-49.
doi: 10.3390/cancers7010439. PMID: 25782007 |
| 275 | The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. | Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. | Cancers (Basel). 2015 Mar 13;7(1):439-49.
doi: 10.3390/cancers7010439. PMID: 25782007 |
| 276 | A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. | Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D,Georgoulias V, Kotsakis A. | J Immunol Res. 2014;2014:659294.
doi: 10.1155/2014/659294. PMID: 25436215 |
| 277 | Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. | Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7.
doi: 10.1007/s00280-015-2707-x. PMID: 25702051 |
| 278 | Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). | Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. | Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7.
doi: 10.1007/s00280-015-2707-x. PMID: 25702051 |
| 279 | Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. | Matikas A, Mistriotis D, Georgoulias V, Kotsakis A. | Clin Lung Cancer. 2015 Jul;16(4):252-61.
doi: 10.1016/j.cllc.2014.12.013. PMID: 25700775 |
| 280 | ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. | Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V | Cancer Invest. 2015 Apr;33(4):107-13.
doi: 10.3109/07357907.2014.1001897. PMID: 25647444 |
| 281 | Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. | Syrios J, Nintos G, Georgoulias V | Expert Rev Anticancer Ther. 2015;15(8):875-84.
doi: 10.1586/14737140.2015.1069186. PMID: 26204906 |
| 282 | Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). | Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. | Lung Cancer. 2015 Apr;88(1):57-62.
doi: 10.1016/j.lungcan.2015.01.012. PMID: 25662596 |
| 283 | Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). | Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. | Lung Cancer. 2015 Apr;88(1):57-62.
doi: 10.1016/j.lungcan.2015.01.012. PMID: 25662596 |
| 284 | Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V | Ann Oncol. 2016 Oct;27(10):1873-8.
doi: 10.1093/annonc/mdw274. PMID: 27502729 |
| 285 | A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. | Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V. | Br J Cancer. 2016 Sep 27;115(7):784-8.
doi: 10.1038/bjc.2016.281. PMID: 27607471 |
| 286 | A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. | Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S. | Cancer Chemother Pharmacol. 2016 May;77(5):949-56.
doi: 10.1007/s00280-016-2997-7. PMID: 26994909 |
| 287 | Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group. | Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V. | Clin Lung Cancer. 2016 Nov;17(6):543-549.
doi: 10.1016/j.cllc.2016.05.009 PMID: 27397849 |
| 288 | Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer. | Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A. | J Thorac Oncol. 2016 Aug;11(8):1263-1272.
doi: 10.1016/j.jtho.2016.04.026. PMID: 27178984 |
| 289 | Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG). | Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A | Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76.
doi: 10.1007/s00280-016-3094-7. PMID: 27335027 |
| 290 | Application of data mining techniques and data analysis methods to measure cancer morbidity and mortality data in a regional cancer registry: The case of the island of Crete, Greece. | Varlamis I, Apostolakis I, Sifaki-Pistolla D, Dey N, Georgoulias V, Lionis C. | Comput Methods Programs Biomed. 2017 Jul;145:73-83.
doi: 10.1016/j.cmpb.2017.04.011. PMID: 28552128 |
| 291 | Classifying circulating tumor cells to monitor cancer progression. | Economopoulou P, Georgoulias V, Kotsakis A | Expert Rev Mol Diagn. 2017 Feb;17(2):153-165.
doi: 10.1080/14737159.2017.1275572. PMID: 28032524 |
| 292 | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. | Bakogeorgos M, Georgoulias V. | Expert Rev Anticancer Ther. 2017 Nov;17(11):1045-1060.
doi: 10.1080/14737140.2017.1374856. PMID: 28868935 |
| 293 | A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. | Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D. | Cell Physiol Biochem. 2017;44(2):594-606.
doi: 10.1159/000485115. PMID: 29161698 |
| 294 | Association analysis identifies 65 new breast cancer risk loci. | Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman et al | Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. PMID: 29059683 |
| 295 | Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. | Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulias V. | Transl Oncol. 2017 Aug;10(4):693-698.
doi: 10.1016/j.tranon.2017.06.005. PMID: 28692881 |
| 296 | Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. | Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E. | Oncotarget. 2017 Jun 27;8(42):72054-72068.
doi: 10.18632/oncotarget.18679. PMID: 29069768 |
| 297 | Distinction between breast cancer cell subtypes using third harmonic generation microscopy. | Gavgiotaki E, Filippidis G, Markomanolaki H, Kenanakis G, Agelaki S, Georgoulias V, Athanassakis I. | J Biophotonics. 2017 Sep;10(9):1152-1162.
doi: 10.1002/jbio.201600173. PMID: 27753229 |
| 298 | Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. | Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S. | Mol Oncol. 2018 Jan;12(1):21-32.
doi: 10.1002/1878-0261.12114. PMID: 28766847 |
| 299 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. | Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A et al | Nat Genet. 2017 Dec;49(12):1767-1778.
doi: 10.1038/ng.3785. PMID: 29058716 |
| 300 | Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. | Matikas A, Foukakis T, Michalakis I, Georgoulias V. | Expert Rev Anticancer Ther. 2017 Apr;17(4):319-326.
doi: 10.1080/14737140.2017.1288105. PMID: 28128984 |
| 301 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. | Martin M, Holmes FA, Ejlertsen B, et al | Lancet Oncol. 2017 Dec;18(12):1688-1700.
doi: 10.1016/S1470-2045(17)30717-9. PMID: 29146401 Clinical Trial. |
| 302 | Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. | Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G. | Oncotarget. 2017 Jan 17;8(3):5309-5322.
doi: 10.18632/oncotarget.14144. PMID: 28029660 |
| 303 | Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. | Papadakis GZ, Mavroudis D, Georgoulias V, Souglakos J, Alegakis AK, Samonis G, Bagci U, Makrigiannakis A, Zoras O. | Growth Horm IGF Res. 2017 Apr;33:28-34.
doi: 10.1016/j.ghir.2017.02.001. PMID: 28258988 |
| 304 | Lung cancer and annual mean exposure to outdoor air pollution in Crete, Greece. | Sifaki-Pistolla D, Lionis C, Koinis F, Georgoulias V, Tzanakis N; Cancer Registry of Crete (CRC). | Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S208-S214.
doi: 10.1097/CEJ.0000000000000407. PMID: 28746162 |
| 305 | Lung cancer and tobacco smoking in Crete, Greece: reflections from a population-based cancer registry from 1992 to 2013. | Sifaki-Pistolla D, Lionis C, Georgoulias V, Kyriakidis P, Koinis F, Aggelaki S, Tzanakis N. | Tob Induc Dis. 2017 Jan 19;15:6.
doi: 10.1186/s12971-017-0114-2. PMID: 28123354 |
| 306 | Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer | Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. | N Engl J Med. 2017 Aug 31;377(9):829-838.
doi: 10.1056/NEJMoa1704795. PMID: 28586279 Clinical Trial. |
| 307 | Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups. | Messaritakis I, Kotsakis A, Georgoulias V. | J Thorac Dis. 2017 Dec;9(12):4817-4820.
doi: 10.21037/jtd.2017.11.106. PMID: 29312665 |
| 308 | Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study. | Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V. | J Geriatr Oncol. 2017 Jan;8(1):23-30.
doi: 10.1016/j.jgo.2016.05.002. PMID: 27264267 |
| 309 | Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer. | Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V. | Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108.
doi: 10.1007/s00280-017-3339-0 PMID: 28523597 |
| 310 | Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. | Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK. | Sci Rep. 2016 Dec 15;6:39247.
doi: 10.1038/srep39247. PMID: 27976733 |
| 311 | Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). | Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A. | Clin Transl Oncol. 2017 Mar;19(3):317-325.
doi: 10.1007/s12094-016-1532-y. PMID: 27492015 |
| 312 | Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. | Matikas A, Mistriotis D, Georgoulias V, Kotsakis A. | Crit Rev Oncol Hematol. 2017 Feb;110:1-12.
doi: 10.1016/j.critrevonc.2016.12.005 PMID: 28109399 |
| 313 | Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. | Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J. | Pharmacogenomics J. 2017 Dec;17(6):506-514.
doi: 10.1038/tpj.2016.63. PMID: 27779244 |
| 314 | Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. | Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A. | Lung Cancer. 2017 Feb;104:16-23.
doi: 10.1016/j.lungcan.2016.12.008. PMID: 28212995 |
| 315 | Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. | Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulias V. | PLoS One. 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. PMID: 28719656 |
| 316 | Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. | Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. | Br J Cancer. 2017 Jun 27;117(1):8-14.
doi: 10.1038/bjc.2017.137. PMID: 28510571 |
| 317 | TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC) | Messaritakis I, Stoltidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, Souglakos J, Georgoulias V. | Sci Rep. 2017 Mar 28;7:45351.
doi: 10.1038/srep45351. PMID: 28349943 |
| 318 | Detection of the T cell activation state using nonlinear optical microscopy. | Gavgiotaki E, Filippidis G, Zerva I, Kenanakis G, Archontakis E, Agelaki S, Georgoulias V, Athanassakis I. | J Biophotonics. 2019 Mar;12(3):e201800277.
doi: 10.1002/jbio.201800277. . PMID: 30353667 |
| 319 | MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. | Koutsioumpa M, Chen HW, O’Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. | Mol Cancer Ther. 2018 Jul;17(7):1430-1440.
doi: 10.1158/1535-7163.MCT-17-1049. PMID: 29703843 |
| 320 | Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. | Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. | Mol Cancer Ther. 2019 Feb;18(2):437-447.
doi: 10.1158/1535-7163.MCT-18-0584. PMID: 30401696 |
| 321 | ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. | Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E | Clin Cancer Res. 2018 Mar 15;24(6):1500-1510.
doi: 10.1158/1078-0432.CCR-17-1181. PMID: 29284708 |
| 322 | ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. | Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E. | Clin Cancer Res. 2018 Mar 15;24(6):1500-1510.
doi: 10.1158/1078-0432.CCR-17-1181. PMID: 29284708 |
| 323 | Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. | Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS. | Breast Cancer Res. 2018 Jul 5;20(1):67.
doi: 10.1186/s13058-018-0993-z. PMID: 29976237 |
| 324 | Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. | Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S. | Mol Oncol. 2018 Jan;12(1):21-32.
doi: 10.1002/1878-0261.12114 PMID: 28766847 |
| 325 | Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. | Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I. | Breast Cancer Res Treat. 2018 May;169(1):105-113.
doi: 10.1007/s10549-018-4661-x. PMID: 29335925 |
| 326 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. | Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al | Am J Hum Genet. 2019 Jan 3;104(1):21-34.
doi: 10.1016/j.ajhg.2018.11.002. PMID: 30554720 |
| 327 | Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. | Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. | Br J Cancer. 2017 Jul 11;117(2):164-170.
doi: 10.1038/bjc.2017.158. PMID: 28641315 |
| 328 | Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. | Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. | Clin Breast Cancer. 2018 Feb;18(1):88-94.
doi: 10.1016/j.clbc.2017.10.013. PMID: 29153775 |
| 329 | Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. | Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. | Clin Breast Cancer. 2018 Feb;18(1):88-94.
doi: 10.1016/j.clbc.2017.10.013. PMID: 29153775 |
| 330 | Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. | Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V. | Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775.
doi: 10.1007/s00280-018-3666-9. PMID: 30094617 |
| 331 | Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). | Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. | J Geriatr Oncol. 2019 Jan;10(1):143-148.
doi: 10.1016/j.jgo.2018.08.002. PMID: 30366852 |
| 332 | Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. | Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. | Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70.
doi: 10.20524/aog.2017.0215. PMID: 29333068 |
| 333 | Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. | Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. | Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70.
doi: 10.20524/aog.2017.0215. PMID: 29333068 |
| 334 | Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. | Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V. | Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704.
doi: 10.20524/aog.2018.0311. PMID: 30386120 |
| 335 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. | Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. | JAMA Oncol. 2018 Sep 1;4(9):1189-1197.
doi: 10.1001/jamaoncol.2018.0775. PMID: 29902295 Clinical Trial. |
| 336 | Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. | Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. | Pharmacogenomics J. 2019 Feb;19(1):15-24.
doi: 10.1038/s41397-018-0013-9. PMID: 29472587 |
| 337 | Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. | Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. | Anticancer Res. 2018 Jun;38(6):3735-3744.
doi: 10.21873/anticanres.12654. PMID: 29848736 |
| 338 | Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. | Pelekanou V, Anastasiou E, Bakogeorgou E, Notas G, Kampa M, Garcia-Milian R, Lavredaki K, Moustou E, Chinari G, Arapantoni P, O’Grady A, Georgoulias V, Tsapis A, Stathopoulos EN, Castanas E. | Steroids. 2019 Feb;142:65-76.
doi: 10.1016/j.steroids.2018.01.008. PMID: 29454903 |
| 339 | Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. | Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A. | Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121.
doi: 10.1177/1758834017750121. PMID: 29383038 |
| 340 | Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. | Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A. | Clin Transl Oncol. 2018 Feb;20(2):140-149.
doi: 10.1007/s12094-017-1702-6. PMID: 28631135 |
| 341 | Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. | Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A. | Clin Transl Oncol. 2018 Feb;20(2):140-149.
doi: 10.1007/s12094-017-1702-6. PMID: 28631135 |
| 342 | Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment. | Messaritakis I, Nikolaou M, Politaki E, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulia N, Georgoulias V, Kotsakis A. | Lung Cancer. 2018 Oct;124:270-278.
doi: 10.1016/j.lungcan.2018.08.021. PMID: 30268472 |
| 343 | Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. | Messaritakis I, Politaki E, Koinis F, Stoltidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulias V, Kotsakis A. | Sci Rep. 2018 Feb 2;8(1):2238.
doi: 10.1038/s41598-018-20502-1. PMID: 29396560 |
| 344 | Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. | Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A | Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. PMID: 28577938
Clinical Trial. |
| 345 | Small cell carcinoma of the stomach: A report of two cases and a review of the literature. | Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N. | Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. PMID: 29896397 |
| 346 | Detection of the T cell activation state using nonlinear optical microscopy. | Gavgiotaki E, Filippidis G, Zerva I, Kenanakis G, Archontakis E, Agelaki S, Georgoulias V, Athanassakis I. | J Biophotonics. 2019 Mar;12(3):e201800277.
doi: 10.1002/jbio.201800277. PMID: 30353667 |
| 347 | Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. | Vougas K, Sakellaropoulos T, Kotsinas A, Foukas GP, Ntargaras A, Koinis F, Polyzos A, Myrianthopoulos V, Zhou H, Narang S, Georgoulias V, Alexopoulos L, Aifantis I, Townsend PA, Sfikakis P, Fitzgerald R, Thanos D, Bartek J, Petty R, Tsirigos A, Gorgoulis VG. | Pharmacol Ther. 2019 Nov;203:107395.
doi: 10.1016/j.pharmthera.2019.107395. PMID: 31374225 |
| 348 | Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. | Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW; V212 Protocol 011 Trial Team. | Lancet Infect Dis. 2019 Sep;19(9):1001-1012.
doi: 10.1016/S1473-3099(19)30310-X. PMID: 31399378 |
| 349 | Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. | Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. | Mol Cancer Ther. 2019 Feb;18(2):437-447.
doi: 10.1158/1535-7163.MCT-18-0584. PMID: 30401696 |
| 350 | First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. | Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R. | Cancer Manag Res. 2019 Dec 12;11:10427-10433.
doi: 10.2147/CMAR.S208712. PMID: 31849532 |
| 351 | Genome-wide association study of germline variants and breast cancer-specific mortality. | Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL et al | Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x..
PMID: 30787463 |
| 352 | PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. | Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V, Lianidou E. | Mol Oncol. 2019 Dec;13(12):2515-2530. doi: 10.1002/1878-0261.12540.
PMID: 31254443 |
| 353 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. | Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J et al | Am J Hum Genet. 2019 Jan 3;104(1):21-34.
doi: 10.1016/j.ajhg.2018.11.002. PMID: 30554720 |
| 354 | Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. | Strati A, Nikolaou M, Georgoulias V, Lianidou ES. | Cells. 2019 Jun 29;8(7):652.
doi: 10.3390/cells8070652. PMID: 31261917 |
| 355 | The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. | Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A, Zacharopoulou N, Alkahtani S, Alarifi S, Stournaras C, Zervakis M, Georgoulias V. | Breast Cancer Res. 2019 Aug 1;21(1):86.
doi: 10.1186/s13058-019-1166-4. PMID: 31370904 |
| 356 | Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. | Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulias V, Souglakos J. | Cancer Res Treat. 2019 Oct;51(4):1518-1526.
doi: 10.4143/crt.2019.008. PMID: 30913862 |
| 357 | Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. | Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V. | Ann Oncol. 2019 Aug 1;30(8):1304-1310.
doi: 10.1093/annonc/mdz193. PMID: 31228203 |
| 358 | Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). | Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. | J Geriatr Oncol. 2019 Jan;10(1):143-148.
doi: 10.1016/j.jgo.2018.08.002. PMID: 30366852 |
| 359 | MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. | Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V. | Target Oncol. 2019 Jun;14(3):285-293.
doi: 10.1007/s11523-019-00647-3. PMID: 31203498 |
| 360 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. | Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, et al | Lancet. 2019 Nov 23;394(10212):1915-1928.
doi: 10.1016/S0140-6736(19)32591-7. PMID: 31679945 Clinical Trial. |
| 361 | Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. | Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. | Pharmacogenomics J. 2019 Feb;19(1):15-24.
doi: 10.1038/s41397-018-0013-9. PMID: 29472587 |
| 362 | CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? | Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK. | Ther Adv Med Oncol. 2019 Jun 12;11:1758835919853193.
doi: 10.1177/1758835919853193 PMID: 31217824 |
| 363 | Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. | Pelekanou V, Anastasiou E, Bakogeorgou E, Notas G, Kampa M, Garcia-Milian R, Lavredaki K, Moustou E, Chinari G, Arapantoni P, O’Grady A, Georgoulias V, Tsapis A, Stathopoulos EN, Castanas E. | Steroids. 2019 Feb;142:65-76.
doi: 10.1016/j.steroids.2018.01.008. PMID: 29454903 |
| 364 | Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. | Syrios J, Kouroussis C, Kotsakis A, Kentepozidis N, Kontopodis E, Kalbakis K, Vardakis N, Hatzidaki D, Polyzos A, Georgoulias V; GU Working Group of the Hellenic Oncology Research Group (HORG). | Minerva Ginecol. 2019 Jun;71(3):182-190.
doi: 10.23736/S0026-4784.19.04249-7. PMID: 30727721 |
| 365 | Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment. | Messaritakis I, Nikolaou M, Koinis F, Politaki E, Koutsopoulos A, Lagoudaki E, Vetsika EK, Georgoulias V, Kotsakis A. | Lung Cancer. 2019 Sep;135:33-39.
doi: 10.1016/j.lungcan.2019.06.025. PMID: 31447000 |
| 366 | BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. | Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E. | Int J Cancer. 2020 Sep 1;147(5):1334-1342.
doi: 10.1002/ijc.32903. PMID: 32022259 |
| 367 | Chemotherapy use near the end-of-life in patients with metastatic breast cancer. | Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulias V, Matikas A. | Breast Cancer Res Treat. 2020 Jun;181(3):645-651.
doi: 10.1007/s10549-020-05663-w. PMID: 32383058 |
| 368 | CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. | Kallergi G, Hoffmann O, Bittner AK, Papadimitriou L, Katsarou SD, Zacharopoulou N, Zervakis M, Sfakianakis S, Stournaras C, Georgoulias V, Kimmig R, Kasimir-Bauer S. | Ther Adv Med Oncol. 2020 Apr 28;12:1758835919895754.
doi: 10.1177/1758835919895754. PMID: 32426042 |
| 369 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. | Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P et al | Nat Genet. 2020 Jan;52(1):56-73.
doi: 10.1038/s41588-019-0537-1. PMID: 31911677 |
| 370 | Third Harmonic Generation microscopy distinguishes malignant cell grade in human breast tissue biopsies. | Gavgiotaki E, Filippidis G, Tsafas V, Bovasianos S, Kenanakis G, Georgoulias V, Tzardi M, Agelaki S, Athanassakis I. | Sci Rep. 2020 Jul 6;10(1):11055.
doi: 10.1038/s41598-020-67857-y. PMID: 32632110 |
| 371 | Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. | Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, et al | Br J Cancer. 2020 May;122(10):1461-1466.
doi: 10.1038/s41416-020-0785-y. PMID: 32210365 |
| 372 | KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. | Mastoraki S, Balgkouranidou I, Tsaroucha E, Klinakis A, Georgoulias V, Lianidou E. | Mol Oncol. 2021 Sep;15(9):2412-2422.
doi: 10.1002/1878-0261.12848. PMID: 33159839 |
| 373 | Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. | Ioannidis G, Papadaki C, Lagoudaki E, Tzardi M, Trypaki M, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. | Anticancer Res. 2020 Feb;40(2):901-913.
doi: 10.21873/anticanres.14023 PMID: 32014934 |
| 374 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. | Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U et al | Lancet Oncol. 2020 Dec;21(12):1574-1588.
doi: 10.1016/S1470-2045(20)30541-6. PMID: 32971005 |
| 375 | Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer | Dimitra Stergiopoulou , Athina Markou , Areti Strati , Martha Zavridou , Eleni Tzanikou , Sophia Mastoraki , Galatea Kallergi , Vassilis Georgoulias , Evi Lianidou | Sci Rep. 2023 Jan 23;13(1):1258.
doi: 10.1038/s41598-022-25400-1. PMID: 36690653 |
| 376 | Genetic Predisposition to Male Breast Cancer: A Case Series | Tryfonopoulos D, Tsoukalas N, Bournakis E, Zagouri F, Kotsakis A, Koumarianou A, Korantzis I, Boukovinas I, Lypas G, Fountzilas G, Michalaki V, Xynogalos S, Linardou H, Papadopoulou E, Nasioulas G, Georgoulias V. | Anticancer Res. 2022 Dec;42(12):5795-5801.
doi: 10.21873/anticanres.16086. PMID: 36456130 |
| 377 | Evidence-Based Conceptual Collection of Methods for Spatial Epidemiology and Analysis to Enhance Cancer Surveillance and Public Health | Sifaki-Pistolla D, Chatzea VE, Frouzi E, Mechili EA, Pistolla G, Nikiforidis G, Georgoulias V, Lionis C, Tzanakis N. | Int J Environ Res Public Health. 2022 Oct 6;19(19):12765.
doi: 10.3390/ijerph191912765. PMID: 36232065 |
| 378 | Spatio-Temporal Variation of Lung Cancer in Crete, 1992-2013. Economic or Health Crisis? | Sifaki-Pistolla D, Chatzea VE, Mechili EA, Koinis F, Georgoulias V, Lionis C, Tzanakis N. | Int J Environ Res Public Health. 2022 Sep 26;19(19):12161.
doi: 10.3390/ijerph191912161. PMID: 36231462 |
| 379 | PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). | Pantazaka E, Ntzifa A, Roumeliotou A, Lianidou E, Georgoulias V, Kotsakis A, Kallergi G. | Biomedicines. 2022 Aug 5;10(8):1893. doi: 10.3390/biomedicines10081893.
PMID: 36009440 |
| 380 | Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.
|
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, Nikolaou M, Georgoulias V.
|
Breast Care (Basel). 2022 Jun;17(3):264-271.
doi: 10.1159/000519729. PMID: 35949417 |
| 381 | Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. | Lampaki S, Mountzios G, Georgoulias V, Rapti A, Xanthakis I, Baka S, Mavroudis D, Samantas E, Athanasiadis E, Zagouri F, Charpidou A, Somarakis A, Papista C, Nikolaou A, Anastasopoulou E, Paparepa Z, Syrigos KN.
|
Future Oncol. 2022 Sep;18(28):3151-3164.
doi: 10.2217/fon-2022-0386. PMID: 35929414 |
| 382 | Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer. | Zafeiriadou A, Kollias I, Londra T, Tsaroucha E, Georgoulias V, Kotsakis A, Lianidou E, Markou A. | Cancers (Basel). 2022 Jun 30;14(13):3237.
doi: 10.3390/cancers14133237. PMID: 35805008 |
| 383 | DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. | Markou Α, Londra D, Tserpeli V, Kollias Ι, Tsaroucha E, Vamvakaris I, Potaris K, Pateras I, Kotsakis Α, Georgoulias V, Lianidou Ε.
|
Clin Epigenetics. 2022 May 10;14(1):61. doi: 10.1186/s13148-022-01283-x.
PMID: 35538556 |
| 384 | PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs. |
Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A, Vasilopoulos Y, Kallergi G. | Cancers (Basel). 2022 Mar 29;14(7):1731.
doi: 10.3390/cancers14071731. PMID: 35406503
|
| 385 | Response to A. Chauhan and A. Pal. | Matikas A, Georgoulias V.
|
Br J Cancer. 2022 Jun;126(11):1661-1662.
doi: 10.1038/s41416-022-01803-9. PMID: 35379931 |
| 386 | Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. | Kallergi G, Kontopodis E, Ntzifa A, Jordana-Ariza N, Karachaliou N, Pantazaka E, Charalambous HA, Psyrri A, Tsaroucha E, Boukovinas I, Koumarianou A, Hatzidaki D, Lianidou E, Georgoulias V, Rosell R, Kotsakis A.
|
Cancers (Basel). 2022 Mar 19;14(6):1574.
doi: 10.3390/cancers14061574. PMID: 35326725 |
| 387 | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.
|
Katsarou SD, Messaritakis I, Voumvouraki A, Kakavogiannis S, Κotsakis A, Alkahtani S, Stournaras C, Martin SS, Georgoulias V, Kallergi G.
|
J Pers Med. 2022 Jan 25;12(2):154.
doi: 10.3390/jpm12020154. PMID: 35207643 |
| 388 |
|
Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, Xenidis N, Katsaounis P, Ardavanis A, Ziras N, Christopoulou A, Rigas G, Kalbakis K, Vardakis N, Emmanouilides C, Athanasiadis I, Anagnostopoulos A, Hatzidaki D, Prinarakis E, Simopoulou F, Kotsakis A, Georgoulias V.
|
Curr Oncol. 2022 Feb 17;29(2):1237-1251.
doi: 10.3390/curroncol29020105. PMID: 35200604 |
| 389 | Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
|
Matikas A, Kotsakis A, Apostolaki S, Politaki H, Perraki M, Kalbakis K, Nikolaou M, Economopoulou P, Hatzidaki D, Georgoulias V.
|
Br J Cancer. 2022 Jun;126(11):1563-1569.
doi: 10.1038/s41416-022-01699-5. PMID: 35145253 |
| 390 | DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment.
|
Ntzifa A, Londra D, Rampias T, Kotsakis A, Georgoulias V, Lianidou E.
|
Cancers (Basel). 2021 Nov 27;13(23):5974.
doi: 10.3390/cancers13235974. PMID: 34885084 |
| 391 | Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis.
|
Vardas V, Politaki E, Pantazaka E, Georgoulias V, Kallergi G.
|
Int J Dev Biol. 2022;66(1-2-3):277-283. doi: 10.1387/ijdb.210180gk.
PMID: 34881791 |
| 392 | 4th Summer School in Immuno-Oncology, July 1st-3rd, 2021, Athens, Greece.
|
Kostopoulos IV, Orologas-Stavrou N, Angelis N, Pateras IS, Kotsakis A, Georgoulias V, Baxevanis CN, Pawelec G, Tsitsilonis OE.
|
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1373-1382.
doi: 10.52586/5030. PMID: 34856774 |
| 393 | Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
|
Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E, Georgoulias V, Ben-Aharon I, Shi Q.
|
J Clin Oncol. 2021 Dec 20;39(36):4009-4019.
doi: 10.1200/JCO.21.02008. PMID: 34752136 |
| 394 | Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects.
|
Chantzara E, Xenidis N, Kallergi G, Georgoulias V, Kotsakis A.
|
Expert Rev Mol Diagn. 2021 Oct;21(10):1037-1048.
doi: 10.1080/14737159.2021.1962710. PMID: 34328384 |
| 395 |
|
Strati A, Zavridou M, Kallergi G, Politaki E, Kuske A, Gorges TM, Riethdorf S, Joosse SA, Koch C, Bohnen AL, Mueller V, Koutsodontis G, Kontopodis E, Poulakaki N, Psyrri A, Mavroudis D, Georgoulias V, Pantel K, Lianidou ES. | Clin Chem. 2021 Oct 1;67(10):1395-1405.
doi: 10.1093/clinchem/hvab099. PMID: 34322698 |
| 396 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.
|
Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E.
|
EClinicalMedicine. 2021 Jun 18;37:100940.
doi: 10.1016/j.eclinm.2021.100940. eCollection 2021 Jul. PMID: 34195574 |
| 397 | Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
|
Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloysis A, Psyrri A, Binas I, Mountzios G, Kentepozidis N, Kotsakis A, Saloustros E, Boutis A, Nikolaidi A, Fountzilas G, Georgoulias V, Chrysanthidis M, Kotteas E, Vo H, Tsiatas M, Res E, Linardou H, Daoussis D, Bompolaki I, Andreadou A, Papaxoinis G, Spyratos D, Gogas H, Syrigos KN, Bafaloukos D.
|
Cancer Immunol Immunother. 2022 Feb;71(2):327-337.
PMID: 34164709 |
| 398 | Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
|
Ntzifa A, Kotsakis A, Georgoulias V, Lianidou E.
|
Cancers (Basel). 2021 May 31;13(11):2736.
doi: 10.3390/cancers13112736. PMID: 34073111 |
| 399 | Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity.
|
Kanaki Z, Voutsina A, Markou A, Pateras IS, Potaris K, Avgeris M, Makrythanasis P, Athanasiadis EI, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulias V, Kotsakis A, Klinakis A.
|
Cancers (Basel). 2021 May 18;13(10):2446.
doi: 10.3390/cancers13102446. PMID: 34070013 |
| 400 | Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
|
Coignard J, Lush M, Beesley J, O’Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, et al. | Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4.
PMID: 33990587 |
| 401 | Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.
|
Markou A, Tzanikou E, Kallergi G, Pantazaka E, Georgoulias V, Kotsakis A, Lianidou E.
|
Front Cell Dev Biol. 2021 Apr 22;9:641978.
doi: 10.3389/fcell.2021.641978. eCollection 2021. PMID: 33968927 |
| 402 | Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.
|
Vetsika EK, Sharma P, Samaras I, Markou A, Georgoulias V, Whiteside TL, Kotsakis A.
|
Cancers (Basel). 2021 Apr 23;13(9):2041.
doi: 10.3390/cancers13092041. PMID: 33922569 |
| 403 | Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC.
|
Pateras IS, Kotsakis A, Avgeris M, Baliou E, Kouroupakis P, Patsea E, Georgoulias V, Menez-Jamet J, Kinet JP, Kosmatopoulos K.
|
Cancers (Basel). 2021 Apr 1;13(7):1658. doi: 10.3390/cancers13071658.
PMID: 33916194 |
| 404 | RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer.
|
Strati A, Nikolaou M, Georgoulias V, Lianidou ES.
|
Diagnostics (Basel). 2021 Mar 14;11(3):513.
doi: 10.3390/diagnostics11030513. PMID: 33799422 |
| 405 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
|
Coignard J, Lush M, Beesley J, O’Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Georgoulias V, et al. | Nat Commun. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3.
PMID: 33597508 |
| 406 | ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies. |
Stergiopoulou D, Markou A, Tzanikou E, Ladas I, Makrigiorgos GM, Georgoulias V, Lianidou E.
|
Cancers (Basel). 2021 Feb 1;13(3):556. doi: 10.3390/cancers13030556.
PMID: 33535614 |
| 407 | Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
|
Papadaki MA, Aggouraki D, Vetsika EK, Xenidis N, Kallergi G, Kotsakis A, Georgoulias V.
|
Anticancer Res. 2021 Feb;41(2):661-670.
doi: 10.21873/anticanres.14817. PMID: 33517270 |
| 408 | Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
|
Spiliotaki M, Kallergi G, Nikolaou C, Xenidis N, Politaki E, Apostolaki S, Georgoulia N, Koinis F, Tsoukalas N, Hatzidaki D, Kotsakis A, Georgoulias V.
|
Cancer Chemother Pharmacol. 2021 Feb;87(2):277-287.
doi: 10.1007/s00280-020-04227-5. PMID: 33515073 |
| 409 | Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
|
Ntzifa A, Strati A, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E.
|
Sci Rep. 2021 Jan 27;11(1):2313.
doi: 10.1038/s41598-021-82068-9. PMID: 33504904 |
| 410 | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
|
Papadaki MA, Messaritakis I, Fiste O, Souglakos J, Politaki E, Kotsakis A, Georgoulias V, Mavroudis D, Agelaki S
|
.Int J Mol Sci. 2021 Jan 18;22(2):925. doi: 10.3390/ijms22020925.
PMID: 33477700 |
| 411 | Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women.
|
Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren , Georgoulias V, et al.
|
N Engl J Med. 2021 Feb 4;384(5):428-439.
doi: 10.1056/NEJMoa1913948. PMID: 33471991 |
| 412 | Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
|
Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, Yamanaka T, Boukovinas I, Hollander NH, Galli F, Yamazaki K, Georgoulias V, Kerr R, Oki E, Lonardi S, Harkin A, Rosati G, Paul J.
|
J Clin Oncol. 2021 Feb 20;39(6):631-641.
doi: 10.1200/JCO.20.01330. PMID: 33439695 |
| 413 | Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
|
André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q.
|
Lancet Oncol. 2020 Dec;21(12):1620-1629.
doi: 10.1016/S1470-2045(20)30527-1. PMID: 33271092 |
| 414 | Common Susceptibility Loci for Male Breast Cancer.
|
Maguire S, Perraki E, Tomczyk K, Jones ME, Fletcher O, Pugh M, Winter T, Thompson K, Cooke R; kConFab Consortium; Trainer A, James P, Bojesen S, Flyger H, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, Silvestri V, Hollestelle A, Hooning MJ, Novaković S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Saloustros E, Georgoulias V, Easton DF, Pharoah P, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Ashworth A, Garcia Closas M, Houlston R, Swerdlow A, Orr N.
|
J Natl Cancer Inst. 2021 Apr 6;113(4):453-461.
doi: 10.1093/jnci/djaa101. PMID: 32785646 |
| 415 | Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340.
|
Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.
|
Ann Oncol. 2020 Mar;31(3):444-445. doi: 10.1016/j.annonc.2020.01.004.
PMID: 32067691 |
| 416 | 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
|
Fortis SP, Kotsakis A, Le Tourneau C, Tsitsilonis OE, Georgoulias V, Baxevanis CN.
|
Cancer Immunol Immunother. 2019 Aug;68(8):1391-1400.
doi: 10.1007/s00262-019-02364-2. PMID: 31309256 |
| 417 | The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.
|
Pistamaltzian NF, Georgoulias V, Kotsakis A.
|
Expert Rev Respir Med. 2019 May;13(5):435-447.
doi: 10.1080/17476348.2019.1593828. PMID: 30869543 |
| 418 | Genome-wide association study of germline variants and breast cancer-specific mortality.
|
Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Georgoulias V,et al.
|
Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x.
PMID: 30787463 |
| 419 | Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer.
|
Lidström T, Cumming J, Gaur R, Frängsmyr L, Pateras IS, Mickert MJ, Franklin O, Forsell MNE, Arnberg N, Dongre M, Patthey C, Öhlund D
|
.Cancer Immunol Res. 2023 Jan 3;11(1):72-92.
doi: 10.1158/2326-6066.CIR-21-1088. PMID: 36478037 |
| 420 | Diagnostically Challenging Subtypes of Invasive Lobular Carcinomas: How to Avoid Potential Diagnostic Pitfalls.
|
Koufopoulos N, Pateras IS, Gouloumis AR, Ieronimaki AI, Zacharatou A, Spathis A, Leventakou D, Economopoulou P, Psyrri A, Arkadopoulos N, Panayiotides IG.
|
Diagnostics (Basel). 2022 Nov 1;12(11):2658.
doi: 10.3390/diagnostics12112658. PMID: 36359501 |
| 421 | Nrf2 Downregulation Contributes to Epithelial-to-Mesenchymal Transition in Helicobacter pylori-Infected Cells.
|
Bacon S, Seeneevassen L, Fratacci A, Rose F, Tiffon C, Sifré E, Haykal MM, Moubarak MM, Ducournau A, Bruhl L, Claverol S, Tokarski C, Gouloumi AR, Pateras IS, Daubon T, Lehours P, Varon C, Martin OCB.
|
Cancers (Basel). 2022 Sep 2;14(17):4316.
doi: 10.3390/cancers14174316. PMID: 36077851 |
| 422 |
|
Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis NN, Glytsou C, Pateras IS, Swain U, Souliotis VL, Georgakilas AG, Geacintov N, Scorrano L, Lukas C, Lukas J, Livneh Z, Lygerou Z, Chowdhury D, Sørensen CS, Bartek J, Gorgoulis VG.
|
Genome Biol. 2022 Apr 28;23(1):107. doi: 10.1186/s13059-022-02678-y.
PMID: 35484586 |
| 423 | Editorial: Reprogramming Stromal Cells in Chronic Inflammation and Cancer.
|
Igea A, Martin OCB, Cooks T, Pateras IS.
|
Front Cell Dev Biol. 2021 Nov 5;9:728439.
doi: 10.3389/fcell.2021.728439. eCollection 2021. PMID: 34858972 |
| 424 | Bacterial genotoxins induce T cell senescence.
|
Mathiasen SL, Gall-Mas L, Pateras IS, Theodorou SDP, Namini MRJ, Hansen MB, Martin OCB, Vadivel CK, Ntostoglou K, Butter D, Givskov M, Geisler C, Akbar AN, Gorgoulis VG, Frisan T, Ødum N, Krejsgaard T.
|
Cell Rep. 2021 Jun 8;35(10):109220. doi: 10.1016/j.celrep.2021.109220.
PMID: 34107253 |
| 425 | Biological Effect of Silver-modified Nanostructured Titanium Dioxide in Cancer.
|
Lagopati N, Kotsinas A, Veroutis D, Evangelou K, Papaspyropoulos A, Arfanis M, Falaras P, Kitsiou PV, Pateras I, Bergonzini A, Frisan T, Kyriazis S, Tsoukleris DS, Tsilibary EC, Gazouli M, Pavlatou EA, Gorgoulis VG.
|
Cancer Genomics Proteomics. 2021 May-Jun;18(3 Suppl):425-439.
doi: 10.21873/cgp.20269. PMID: 33994365 |
| 426 | Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence.
|
Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, Roumelioti FM, Chiourea M, Mourkioti I, Paparouna E, Zampetidis CP, Gumeni S, Trougakos IP, Pefani DE, O’Neill E, Gagos S, Eliopoulos AG, Fendler W, Chowdhury D, Bartek J, Gorgoulis VG.
|
BMC Genomics. 2021 May 5;22(1):327. doi: 10.1186/s12864-021-07608-z.
PMID: 33952190 |
| 427 | Influence of the microenvironment on modulation of the host response by typhoid toxin.
|
Martin OCB, Bergonzini A, Lopez Chiloeches M, Paparouna E, Butter D, Theodorou SDP, Haykal MM, Boutet-Robinet E, Tebaldi T, Wakeham A, Rhen M, Gorgoulis VG, Mak T, Pateras IS, Frisan T.
|
Cell Rep. 2021 Apr 6;35(1):108931.
doi: 10.1016/j.celrep.2021.108931. PMID: 33826883 |
| 428 | Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity.
|
Moustakas II, Katsarou A, Legaki AI, Pyrina I, Ntostoglou K, Papatheodoridi AM, Gercken B, Pateras IS, Gorgoulis VG, Koutsilieris M, Chavakis T, Chatzigeorgiou A
|
.Int J Mol Sci. 2021 Mar 26;22(7):3446. doi: 10.3390/ijms22073446.
PMID: 33810566 |
| 429 | Nuchal-type Fibroma: Single-Center Experience and Systematic Literature Review.
|
Kostakis ID, Feretis T, Damaskos C, Garmpis N, Liapis G, Pateras I, Garmpi A, Georgakopoulou VE, Antoniou EA.
|
In Vivo. 2020 Sep-Oct;34(5):2217-2223. doi: 10.21873/invivo.12032.
PMID: 32871744 |
| 430 | Unique Spatial Immune Profiling in Pancreatic Ductal Adenocarcinoma with Enrichment of Exhausted and Senescent T Cells and Diffused CD47-SIRPα Expression.
|
Papalampros A, Vailas M, Ntostoglou K, Chiloeches ML, Sakellariou S, Chouliari NV, Samaras MG, Veltsista PD, Theodorou SDP, Margetis AT, Bergonzini A, Karydakis L, Hasemaki N, Havaki S, Moustakas II, Chatzigeorgiou A, Karamitros T, Patsea E, Kittas C, Lazaris AC, Felekouras E, Gorgoulis VG, Frisan T, Pateras IS. | Cancers (Basel). 2020 Jul 7;12(7):1825. doi: 10.3390/cancers12071825.
PMID: 32645996
|
| 431 | MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.
|
Magkouta SF, Pappas AG, Vaitsi PC, Agioutantis PC, Pateras IS, Moschos CA, Iliopoulou MP, Kosti CN, Loutrari HV, Gorgoulis VG, Kalomenidis IT.
|
JCI Insight. 2020 Jun 18;5(12):e134885. doi: 10.1172/jci.insight.134885.
PMID: 32554927 |
| 432 | Conditioning attenuates kidney and heart injury in rats following transient suprarenal occlusion of the abdominal aorta.
|
Karageorgiadi DM, Tsilimigras DI, Selemenakis P, Vlachou V, de Lastic AL, Rodi M, Chatziathanasiou D, Savvatakis K, Antoniou N, Deli AC, Papalampros A, Filis KA, Mouzaki A, Varvarigou A, Zografos G, Gorgoulis VG, Pateras IS, Sigala F.
|
Sci Rep. 2020 Mar 19;10(1):5040.
doi: 10.1038/s41598-020-61268-9. PMID: 32193441 |
| 433 | TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
|
Moukengue B, Brown HK, Charrier C, Battaglia S, Baud’huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F
|
.EBioMedicine. 2020 Mar;53:102704. doi: 10.1016/j.ebiom.2020.102704. Epub 2020 Mar 7.
PMID: 32151797 |
| 434 | Notch controls urothelial integrity in the mouse bladder.
|
Paraskevopoulou V, Bonis V, Dionellis VS, Paschalidis N, Melissa P, Chavdoula E, Vasilaki E, Pateras IS, Klinakis A.
|
JCI Insight. 2020 Feb 13;5(3):e133232. doi: 10.1172/jci.insight.133232.
PMID: 32051338 |